Strides Arcolab's wholly owned subsidiary, Onco Therapies Ltd, has received approvals from US FDA for Cytarabine injection 20 mg/ mL, packaged in 500 mg/ 25 mL multiple-dose vials, 20 mg/ mL, packaged in 100 mg/5 mL single-dose vial and 20 mg/mL, packaged in 1000 mg/50 mL packaged.

Cytarabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Cytarabine is used to treat different forms of leukaemia, including acute and chronic myelogenous and acute lymphocytic leukaemia. It is also used to treat lymphoma, meningeal leukaemia and lymphoma (cancers found in the lining of the brain and spinal cord).

According to IMS data, the US market for Cytarabine is approximately USD 12.3 million. Cytarabine is part of the oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly.